Skip to NavigationSkip to content

Bayer and J&J successfully reverse $28 million Xarelto court payout

Published on 10/01/18 at 09:46am

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge overturned the award to a couple accusing the pair of firms of failing to adequately warn patients of the internal bleeding risks of its blood thinner drug Xarelto.

Lynn Hartman had originally taken Bayer and J&J’s jointly-developed therapy for a year for the treatment of atrial fibrillation before being hospitalised with severe gastrointestinal bleeding in June 2014. She blamed the condition on Xarelto, suing the drugmakers alongside her husband in 2015.

The trial became one of the estimated 21,000 Xarelto-related cases pending in federal and state courts, and the first of such cases pending in Philadelphia court. The couple were eventually awarded $1.8 million in compensatory damages and $26 million in punitive damages in December.

The plaintiffs of these many cases assert that Bayer and J&J did not provie suitable warning over the dangers of irreversible bleeding when using Xarelto, though the pair assert that this risk is fully listed on the product’s label. “Bayer stands behind the safety and efficacy of Xarelto and will continue to vigorously defend it,” Bayer said in a statement.

Xarelto was approved by the FDA in 2011 for the treatment of atrial fibrillation and the treatment and reduction of deep vein thrombosis and pulmonary embolism.  

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches